Clinical trial
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland…
NCT00002632 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00002632 |
|---|---|
| Title | Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer |
| Official title | PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel |
| Enrollment | 32 |
| Start date | May 30, 1995 |
| Primary completion | May 1, 2002 |
| First posted | Jun 10, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: